NDLI: Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Matias, Patrícia João Jorge, Cristina Ferreira, Carina Borges, Marília Aires, Inês Amaral, Tiago Gil, Célia Cortez, José Ferreira, Aníbal
Description	Country affiliation: Portugal Author Affiliation: Matias PJ ( Hemodial-Dialysis Unit, Quinta da Mina, Lote 3 r/c, 2600-063 Vila Franca de Xira, Portugal. patriciajoaomatias@gmail.com)
Abstract	BACKGROUND AND OBJECTIVES: Vitamin D deficiency is highly prevalent in chronic kidney disease. The aim of this study was to evaluate the effects of oral cholecalciferol supplementation on mineral metabolism, inflammation, and cardiac dimension parameters in long-term hemodialysis (HD) patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This 1-year prospective study included 158 HD patients. Serum levels of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)(2)D], intact parathyroid hormone, and plasma brain natriuretic peptide as well as circulating bone metabolism and inflammation parameters were measured before and after supplementation. Baseline 25(OH)D and 1,25(OH)(2)D levels were measured twice (end of winter and of summer, respectively). Therapy with paricalcitol, sevelamer, and darbepoietin was evaluated. RESULTS: There was an increase in serum 25(OH)D and 1,25(OH)(2)D levels after supplementation. Conversely, serum calcium, phosphorus, and intact parathyroid hormone were decreased. There was a reduction in the dosage and in the number of patients who were treated with paricalcitol and sevelamer. Darbepoietin use was also reduced, with no modification of hemoglobin values. Serum albumin increased and C-reactive protein decreased during the study. Brain natriuretic peptide levels and left ventricular mass index were significantly reduced at the end of the supplementation. CONCLUSIONS: Oral cholecalciferol supplementation in HD patients seems to be an easy and cost-effective therapeutic measure. It allows reduction of vitamin D deficiency, better control of mineral metabolism with less use of active vitamin D, attenuation of inflammation, reduced dosing of erythropoiesis-stimulating agents, and possibly improvement of cardiac dysfunction.
File Format	HTM / HTML
ISSN	15559041
e-ISSN	1555905X
DOI	10.2215/CJN.06510909
Journal	Clinical Journal of the American Society of Nephrology
Issue Number	5
Volume Number	5
Language	English
Publisher	American Society of Nephrology
Publisher Date	2010-05-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Kidney Diseases Therapy Prospective Studies Erythropoietin Biological Markers Vitamin D Deficiency Polyamines Blood Time Factors Vitamin D Etiology Bone Density Conservation Agents Hematinics Inflammation Mediators Administration, Oral Metabolism Drug Effects Hypertrophy, Left Ventricular Chronic Disease Chelating Agents Analogs & Derivatives Calcium Calcitriol Parathyroid Hormone Natriuretic Peptide, Brain C-reactive Protein Sevelamer Darbepoetin Alfa Prevention & Control Complications Cholecalciferol Drug Therapy Discipline Nephrology Phosphorus Administration & Dosage Vitamins Therapeutic Use Serum Albumin Bone Remodeling Dietary Supplements Ergocalciferols Renal Dialysis
Content Type	Text
Resource Type	Article
Subject	Transplantation Critical Care and Intensive Care Medicine Nephrology Epidemiology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Vitamin D in health and disease.

New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Effects of treatment of renal osteodystrophy on bone histology.

Response of different PTH assays to therapy with sevelamer or $CaCO_{3}$ and active vitamin D sterols

A D-vitamin-hiány csontrendszeri és csontrendszeren kívüli következményei.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?

Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa.

Darbepoetin alfa for anemia with myelodysplastic syndrome.

Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs.

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Similar Documents

Vitamin D in health and disease.

New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Effects of treatment of renal osteodystrophy on bone histology.

Response of different PTH assays to therapy with sevelamer or $CaCO_{3}$ and active vitamin D sterols

A D-vitamin-hiány csontrendszeri és csontrendszeren kívüli következményei.

How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Can reduction of inflammation improve ESA dose response?

Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa.

Darbepoetin alfa for anemia with myelodysplastic syndrome.

Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analogs.

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.